Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ROCKET PHARMACEUTICALS, INC.

Get SEC filing alerts via email and in your feed for ROCKET PHARMACEUTICALS, INC.

RCKT RCKTW

ROCKET PHARMACEUTICALS, INC.

About ROCKET PHARMACEUTICALS, INC.

Rocket Pharmaceuticals is a biotech company specializing in developing gene therapies for rare, devastating diseases. Its focus includes in vivo AAV-based treatments for conditions like Danon disease and cardiomyopathies, as well as ex vivo lentiviral programs for hematologic disorders such as Fanconi anemia and LAD-I. The company aims to deliver potentially curative, first-in-class therapies targeting unmet medical needs in pediatric and adult patients worldwide.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from ROCKET PHARMACEUTICALS, INC.

1
1
ROCKET PHARMACEUTICALS, INC. Rocket Pharmaceuticals Reports $47.6 Million Net Loss in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
ROCKET PHARMACEUTICALS, INC. Rocket Pharmaceuticals Reports $223.1 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
ROCKET PHARMACEUTICALS, INC. Rocket Pharmaceuticals Reports $50.3 Million Net Loss in Q3 2025, Reduces Operating Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ROCKET PHARMACEUTICALS, INC. Rocket Pharmaceuticals Reports Q2 2025 Financial Results with $68.9M Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ROCKET PHARMACEUTICALS, INC. Rocket Pharmaceuticals Reports $61.3 Million Net Loss in Q1 2025, Focuses on Gene Therapy Development

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ROCKET PHARMACEUTICALS, INC. Rocket Pharmaceuticals Reports Financial Results, Advances Gene Therapy Programs

Via official filing (AI summary) | over 1 year ago | 0 comments